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Autoregulated glomerular filtration rate during candesartan mal kidney, autoregulatory mechanisms are efficient for
treatment in hypertensive type 2 diabetic patients. controlling and stabilizing GFR during changes in systemic
Background. Impaired autoregulation of the glomerular fil- blood pressure by changing in the renal vascular resistance.tration rate (GFR) implies disturbances in the downstream
We have previously demonstrated that autoregulationtransmission of the systemic blood pressure into the glomeru-
of GFR is impaired or abolished in type 1 [2] and type 2lus, leading to capillary hypertension or hypotension dependent
of the level of blood pressure. The impact on renal autoregula- diabetic patients with diabetic nephropathy [3]. Impaired
tion of different antihypertensive drugs in animals has been autoregulation of GFR implies disturbances in the down-
elucidated, whereas information in humans is lacking.
stream transmission of the systemic blood pressure intoMethods. A randomized, double-blind crossover study with
the glomerulus that lead to capillary hypertension orcandesartan cilexetil 16 mg o.d. and placebo was performed in
17 hypertensive type 2 diabetic patients without nephropathy. hypotension, depending on the level of systemic blood
Each treatment arm lasted four weeks. On the last day, GFR pressure. Increased glomerular capillary pressure is an
(single shot [51Cr] EDTA plasma clearance technique for 4 hours) important factor in the development and progression of
was measured twice between 8 a.m. and 5 p.m., first without
experimental diabetic and nondiabetic glomerulopathiesclonidine and then after an intravenous injection of clonidine
[4]. The relationship between changes in renal perfusion75 g. Blood pressure (Takeda TM2420, A&D, Tokyo, Japan)
was measured every ten minutes, and the urinary albumin pressure and renal autoregulation during treatment with
excretion rate (UAER) was measured by ELISA during each different antihypertensive drugs in nondiabetic animals
GFR determination. has been elucidated [5–14]. Unfortunately, such informa-Results. Candesartan induced a mean (SE) reduction in mean
tion in diabetic animals and diabetic patients is com-arterial blood pressure (MABP) of 6 (2) mm Hg (P  0.02)
and had a tendency to reduce UAER (P  0.07), while GFR pletely lacking.
remained unchanged (95 vs. 93 mL/min/1.73 m2). Clonidine Therefore, the aim of our randomized double-blind
reduced MABP with 17 (2) versus 16 (1) mm Hg during placebo crossover study was to investigate the effect of angioten-
versus candesartan 16 mg o.d., respectively (NS). GFR dimin-
sin II receptor blockade on the autoregulation of GFRished in average from 95 (3) to 92 (4) mL/min/1.73 m2 with
in hypertensive type 2 diabetic patients without overtplacebo (NS), and from 93 (3) to 89 (4) mL/min/1.73 m2 during
treatment with candesartan (NS). The mean difference (95% nephropathy.
CI) in the changes in GFR between the examination with
placebo and with candesartan was 0.1 (5.5 to 5.8) mL/min/
1.73 m2 (NS). METHODS
Conclusion. Candesartan reduces blood pressure without ad-
Seventeen hypertensive type 2 diabetic patients wereversely altering the preserved ability to autoregulate GFR in
selected who were without overt nephropathy in orderhypertensive type 2 diabetic patients without nephropathy.
to have a group in need of antihypertensive treatment
but with normal or only slightly impaired autoregulation
The ability of the kidney to maintain a constant glomer- (Table 1). The patients were considered to have type 2
ular filtration rate (GFR) over a wide range of renal per- diabetes if at onset of diabetes they were treated with
fusion pressures is termed autoregulation [1]. In the nor- diet alone or in combination with oral hypoglycemic
agents, or if they were treated with insulin, had an onset
of diabetes after the age of 40 years and had a bodyKey words: albuminuria, blood pressure, angiotensin II receptor block-
ade, renal hemodynamics, diabetes mellitus. weight in excess of their ideal body weight at the time
of diagnosis [15]. All lean insulin-treated patients had aReceived for publication October 16, 2000
glucagon test performed, and type 2 diabetes was diag-and in revised form April 23, 2001
Accepted for publication April 24, 2001 nosed if a stimulated C-peptide value was equal to or
above 0.60 pmol/mL [15]. Patients were considered to 2001 by the International Society of Nephrology
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have arterial hypertension if they were treated with anti- and 240 minutes after the second injection of 8.0 MBq
of 51Cr EDTA. The small underestimation (10%) of 51Cr-hypertensive drugs or had a systolic blood pressure
above 140 mm Hg and/or diastolic blood pressure above EDTA clearance versus clearance of inulin was corrected
by multiplying the EDTA clearance by 1.10 [22]. The90 mm Hg [16].
All subjects gave informed consent to participate in results were standardized for a 1.73 m2 body surface area,
using the patient’s surface area at the start of the study.the study, and the study design was approved by the
local ethical committee. It was conducted according to The patients rested in a supine position during the entire
investigation.the principles expressed in the Declaration of Helsinki.
Before conducting the present study, we evaluated the Blood pressure and heart rate were measured while
the patient was in the supine position with the Takedareproducibility of the GFR and urinary albumin excre-
tion rate (UAER) by measuring them twice during the TM2420 device (A&D, Tokyo, Japan) using the left arm
and appropriate cuff sizes [25  12 cm (upper arm cir-same day (8 a.m. to 12 p.m. vs. 12:30 p.m. to 4:30 p.m.).
This evaluation was carried out in 13 (6 women and cumference35 cm) and 30 15 cm (upper arm circum-
ference35 cm)] at baseline and every 10 minutes during7 men) type 2 diabetic patients using exactly the same
methods as described later in this article, but without the GFR measurement. Mean arterial blood pressure
(MABP) was calculated as diastolic blood pressure plusclonidine. The mean coefficient of variation in GFR was
3.9% compared with a mean coefficient of variation in one third of the pulse amplitude.
The UAER was determined during each four-hourGFR from day-to-day of 4.5% [17]. The variation co-
efficient was 19.9% for UAER during the GFR mea- period by using an enzyme-linked immunoabsorbent
assay (ELISA) with an intra-assay variation of 2.1% andsurement compared with a day-to-day variation of 23 to
58%, with the lowest variation coefficient between the interassay variation of 8.3% [24]. Fractional clearance of
albumin was obtained by dividing the clearance of albu-night collections [18–21]. No systematic alterations were
demonstrated in the GFR and UAER, thus ruling out min (calculated as UV/P; where U is the urine albumin
concentration, V is urine flow, and P is plasma albumintime-dependent changes within the period from 8 a.m.
to 4:30 p.m. Furthermore, no difference was found in concentration) with the simultaneously measured GFR.
Blood glucose was measured by a glucose-oxidaseMABP during the two GFR measurements (mean differ-
ence 2.2 mm Hg; 5.4 to 1.1 mm Hg, 95% CI). method on an autoanalyzer (one touch 2; Lifescan, Mil-
pitas, CA, USA) every 30 minutes during the investiga-All antihypertensive treatment was stopped at least
14 days before randomization. A randomized, double- tion. Hemoglobin A1c (HbA1c) was measured by high
performance liquid chromatography (Variant; Bio-Radblinded crossover study was performed in which each
arm lasted four weeks, with no washout periods between Laboratory, Hercules, CA, USA). The normal range of
HbA1c in our laboratory is 4.1 to 6.4%. Serum potassiumthe two arms. The patients were randomized to treat-
ment with candesatan cilexetil 16 mg o.d. (AstraZeneca was measured by an indirect ion-selective method
(BM/HITACHI system, Boehringer Mannheim GmbH,A/S, Albertslund, Denmark) or matching placebo for
four weeks each. Tablet counting assessed compliance. Roche Laboratory Systems, Mannheim, Germany) with
a normal range of 3.5 to 5.0 mmol/L.GFR was measured twice on the same day at the end of
each treatment period: first without clonidine (baseline)
Statistical analysisand second after a slow intravenous injection (10 min)
of clonidine 75 g (Boehringer, Ingeheim, Germany). Normally distributed data are expressed as means and
standard deviation (SD) or standard error (SE). All com-The GFR was measured during two four-hour peri-
ods: one from 8 a.m. to 12 p.m. after a single intravenous parisons of normally distributed parameters were carried
out with the Student t test, using a paired design. Allinjection of 1.5 MBq of Na 51Cr-labeled eidetic acid
([51Cr]EDTA), [22, 23] and the other from 12:30 p.m. to blood pressure measurements during the four-hour pe-
riod were used to calculate mean values and standard4:30 p.m. after a single intravenous injection of 8.0 MBq
of 51Cr EDTA by determination of the radioactivity in error during each examination in each patient. The dif-
ferences between the two examinations were trans-venous blood samples taken at 180, 200, 220, and 240
minutes after each injection. To correct for background formed into relative changes and linear regression analy-
sis was used to analyze for correlations. Values forradioactivity, a venous blood sample was taken at the
first GFR determination before the injection of 51Cr- UAER and fractional clearance of albumin were loga-
rithmically transformed before inclusion in the analysisEDTA. The background radioactivity was subtracted
from the individual radioactivity measured in both GFR because of their positive skewed distribution. Data were
tested for a period effect and a treatment-period interac-measurements. The residual radioactivity from the first
measurement was calculated for each of time points in tion with a two-sample t test. All calculations were made
using SPSS for Windows (SPSS Inc., Chicago, IL, USA).the second GFR measurement and subtracted from the
measured radioactivity at the time points 180, 200, 220, A P value of0.05 was considered significant (two tailed).
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Table 1. Baseline clinical data of 17 hypertensive type 2 diabetic patients without overt nephropathy
Known duration
Age of diabetes
BMI Blood pressure Antidiabetic
Subject Sex years kg/m2 mm Hg Retinopathy treatmenta
1 F 54 15 19 150/90 Nil 3
2 M 54 15 23 153/88 Simplex 3
3 F 52 21 27 152/94 Simplex 3
4 M 54 16 26 142/80 Simplex 3
5 M 54 6 26 168/94 Proliferative 1
6 M 67 24 33 170/93 Simplex 3
7 M 63 6 25 140/90 Nil 2
8 F 61 12 25 144/85 Simplex 3
9 M 66 13 22 153/86 Nil 3
10 F 65 3 26 163/90 Nil 3
11 M 56 7 27 169/99 Nil 4
12 F 60 15 32 160/88 Proliferative 3
13 M 61 9 28 158/76 Proliferative 2
14 F 50 12 29 155/87 Nil 3
15 M 61 13 29 150/94 Simplex 3
16 F 60 18 38 152/82 Nil 3
17 F 69 14 32 168/104 Nil 2
Mean (SD) 59 (6) 13 (5) 27 (5) 156/89 (9/7)
a Type of treatment: 1, Diet; 2, oral hypoglycemic treatment; 3, insulin treatment; 4, insulin and oral hypoglycemic treatment
RESULTS cantly in patients with UAER values above the median
(6 g/min, P 0.05). Candesartan induced no significantClinical and demographic data for the 17 hypertensive,
difference in the fractional clearance of albumin (logtype 2 diabetic patients without overt nephropathy is
mean difference, 0.12; 95% CI 0.03 to 0.27).shown in Table 1. Patient numbers 1, 4, 13, and 14 had
An intravenous injection of clonidine 75 g inducednever received antihypertensive treatment. All patients
an equal and significant reduction in MABP of 17 had normal GFR.
2 mm Hg (mean  SE) and 16  1 mm Hg during theThe patients received the placebo treatment for 28 (2)
placebo and candesartan treatment, respectively (P days and candesartan 16 mg for 29 (3) days [mean (SD);
0.001; Table 2). The mean difference in changes ofNS]. During the first treatment period, eight patients
MABP (95% CI) between the placebo and candesartanreceived candesartan, and nine received placebo. The
treatment was 1.3 (1.2 to 3.8) mm Hg (Table 3). Cloni-patients took 99% (range of 85% to 100%) of the tablets
dine reduced MABP below 80 mm Hg (the lower normalduring the placebo treatment and 99% (range of 90%
limit of autoregulation, that is, 80 mm Hg found in animalto 107%) of the tablets during the candesartan treat-
studies) [1, 25–28] in three patients (numbers 9, 14 andment (NS).
16) during the candesartan treatment, while no patientNeither a period effect [placebo/candesartan vs. can-
had a reduction below 80 mm Hg during the examinationdesartan/placebo; average difference 1.8 (7.3) vs. 1.8
with placebo.(14.3), mean  (SD), P  0.53], nor a treatment period
The GFR diminished from (mean  SE) 95  3 tointeraction (placebo/candesartan vs. candesartan/placebo;
92  4 mL/min/1.73 m2 (NS) with the placebo treatmentaverage levels 5 (10) vs. 2 (9), P  0.54) was found upon
and from 93  3 to 89  4 mL/min/1.73 m2 with theGFR.
candesartan treatment (NS; Table 2). The mean differ-The mean difference in arterial blood pressure (95%
ence in the changes of GFR between the placebo andCI) between the two baseline measurements revealed
candesartan treatments was 0.1 (5.5 to 5.8) mL/min/that candesartan cilexetil 16 mg o.d. reduced systolic
1.73 m2 (NS) (Table 3). The same number of patientsblood pressure with 12 (range of 3 to 20) mm Hg (P 
(N  3) had a reduction in GFR 13% (our upper limit0.02) and had a tendency to reduce diastolic blood pres-
of normal autoregulation of GFR in healthy humanssure [4 (0.5 to 7.3) mm Hg, P  0.08], or in other
[29]) during the placebo and candesartan treatments.words, MABP was reduced from 110 (2.2) mm Hg to 104
Two of these patients had a reduction of GFR 13%(2.4) mm Hg (P  0.02) by treatment with candesartan
during both examinations. Twelve of the 17 patients hadcilexetil 16 mg o.d. per day. Candesartan did not affect
a reduction of GFR during the placebo treatment, whileGFR; the mean difference between the two baseline
10 of the patients had a reduction of GFR during themeasurements was 2.8 (4.2 to 9.8) mL/min/1.73 m2. The
examination with candesartan (Fig. 1).mean difference in log UAER was 0.13 (0.01 to 0.28)
g/min (P  0.07). Candesartan reduced UAER signifi- Clonidine induced a significant reduction in UAER
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Table 2. Arterial blood pressure (BP), glomerular filtration rate (GFR) and urinary albumin excretion rate (UAER) in 17 hypertensive
type 2 diabetic patients without overt nephropathy
BP mm Hg GFR ml/min/1.73 m2 UAERa lg/min
Before After Before After Before After
Subjects clonidine clonidine clonidine clonidine clonidine clonidine
Placebo
1 134/831/1 107/711/1 92 101 5 4
2 148/922/1 132/752/1 117 109 2 5
3 148/922/1 132/752/1 101 84 30 9
4 133/861/2 118/741/1 86 112 14 9
5 175/932/1 142/762/1 123 117 5 4
6 168/872/1 137/732/1 88 94 45 14
7 156/972/1 147/922/2 108 102 7 6
8 149/941/2 112/721/1 84 78 5 3
9 162/961/2 127/713/2 94 78 27 18
10 143/892/1 110/751/1 69 61 4 3
11 165/932/2 139/772/1 88 94 5 3
12 144/872/1 134/842/1 102 91 11 5
13 142/742/1 125/692/1 81 73 5 4
14 150/794/1 107/672/2 98 107 6 4
15 142/802/1 122/692/2 105 91 7 6
16 148/832/2 122/712/1 101 88 5 2
17 187/1052/1 160/932/1 86 81 88 30
Mean  SE 153/894/2 128/764/2 953 924 91 61
P value 0.001 NS 0.01
Candesartan
1 120/771/1 108/671/1 99 98 1 10
2 153/972/3 122/751/2 88 95 5 4
3 140/771/1 121/703/2 98 76 17 10
4 132/791/2 123/731/1 120 120 21 11
5 177/902/2 141/763/2 101 104 5 16
6 136/812/1 118/672/1 84 93 16 9
7 153/1032/1 134/912/2 110 104 6 6
8 141/881/1 106/702/2 90 78 6 2
9 140/821/1 106/612/2 93 70 13 6
10 120/861/2 101/702/1 65 64 4 4
11 148/941/1 134/802/1 83 88 4 3
12 144/882/1 127/822/1 85 98 5 2
13 170/862/2 149/861/3 87 78 5 5
14 116/782/1 88/591/1 91 100 6 2
15 140/822/1 115/712/1 97 91 7 4
16 117/733/1 107/632/2 98 82 4 2
17 149/912/2 118/773/2 86 76 20 8
Mean  SE 141/854/2 119/734/2 933 894 71 51
P value 0.001 NS NS
Results are expressed as mean  SE and a geometric mean  antilog SE.
Table 3. Changes in glomerular filtration rate (GFR), systolic and diastolic blood pressure (BP), urinary albumin excretion rate (UAER)
and blood glucose (BG) induced by intravenous injection of clonidine 75 g in 17 hypertensive type 2 diabetic patients without overt
nephropathy treatment with placebo (P) or candesartan 16 mg (C)
Before After Mean difference
Treatment Parameter clonidine clonidine (95% confidence interval) P value
(P) GFR 95 92 3.6 (2.2 to 9.4) NS
(C) GFR ml/min/1.73 m2 92 89 3.5 (2.0 to 9.0) NS
(P) Systolic and 153 128 25 (20 to 30) 0.001
diastolic (BP) 89 76 13 (10 to 16) 0.001
(C) Systolic and 141 119 22 (18 to 27) 0.001
diastolic (BP) mm Hg 85 73 13 (10 to 16) 0.001
(P) Log UAER 0.96 0.76 0.20 (0.09 to 0.31) 0.01
(C) Log UAER lg/min 0.82 0.70 0.12 (0.07 to 0.32) NS
(P) BG 8.8 8.0 0.8 (1.7 to 3.3) NS
(C) BG mmol/L 6.8 8.4 1.6 (3.7 to 0.6) NS
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end of each treatment period 8.0 (0.8)% vs. 7.9 (0.8)%
(placebo vs. candesartan treatment period, mean (SD),
and blood glucose was not changed by intravenous injec-
tion of clonidine (Table 3).
None of the patients had adverse or seriously adverse
events, and serum potassium was normal in all 17 at the
end of each treatment period. Furthermore, no changes
were revealed in serum potassium between the two treat-
ments [0.01 (0.11 to 0.14) mmol/L].
Apart from dry mouth and sleepiness, no side effects
were observed after the clonidine injection.
DISCUSSION
Our randomized, double-blinded crossover study in
hypertensive patients with type 2 diabetes without overt
nephropathy showed preserved autoregulation of GFR
during treatment with candesartan 16 mg o.d. This was
found despite the fact that three candesartan-treated pa-
tients had MABP values lower that the normal limit of
autoregulation (80 mm Hg). Treatment with candesartan
16 mg o.d. reduced significantly arterial blood pressure
and had a tendency to reduce UAER, while GFR re-
mained unchanged. Similar results have been obtained
in hypertensive patients without diabetes [30].
Although candesartan treatment had a tendency to
reduce UAER without significantly reducing GFR, our
data do not permit the beneficial effect on UAER to be
ascribed specifically to candesartan therapy rather than
to the concomitant blood pressure reductions that were
obtained. Such an interpretation is supported by the fact
that the clonidine injection induced acute blood pressure
reduction resulted in a decrease in UAER during the pla-
cebo treatment, but not the candesartan period, probably
because the blood pressure and UAER were already
reduced during the candesartan period as compared to
the placebo period.
We chose to evaluate hypertensive type 2 patients with-
out overt nephropathy, because we had previously dem-
onstrated an impaired/abolished GFR autoregulation in
type 1 and type 2 diabetic patients with diabetic nephrop-
athy and in patients with nondiabetic nephropathies [2,Fig. 1. Relative change in glomerular filtration rate (GFR) (percentage
3, 29]. The effects of candesartan on autoregulation ofchange of control GFR) and relative change in mean arterial blood
pressure (MABP) (percentage change of control MABP) induced by GFR in patients with overt nephropathy were not evalu-
intravenous injection of clonidine. (A) Treatment with placebo. (B) ated, because a reduction in arterial blood pressure inTreatment with candesartan 16 mg o.d.
these patients would reduce GFR irrespectively of the
chosen antihypertensive drug due to an impaired/abol-
ished GFR autoregulation. Consequently, if we had de-
during the placebo treatment, while intravenous injection cided to use patients with overt nephropathy, it only
of clonidine induced no significant changes in UAER would have been possible to evaluate whether candesar-
during the candesartan treatment (Table 2). tan could restore autoregulation in type 2 diabetic pa-
No significant correlation was found between the rel- tients with nephropathy. Type 2 diabetic patients with
ative changes in GFR (%) and the relative changes in overt nephropathy have severe structural lesions such as
MABP (%) during the two treatments (Fig. 1). arteriolar hyalinosis [31, 32], which probably causes an
irreversible impairment of kidney autoregulation. There-The metabolic control (HbA1c) was the same at the
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fore, the possibility of such a short-term effect of treat- This hemodynamic alteration is associated with an in-
crease in albuminuria and acceleration of glomerular dam-ment with candesartan on autoregulation was regarded
as highly unlikely. age [39]. Consequently, it is of major pathophysiological
importance that the GFR autoregulation is intact, as dem-Clonidine was used as a blood pressure-lowering drug
in the previous and the present study because it has no onstrated in our hypertensive diabetic patients. In this con-
text, it is also important to select an antihypertensive treat-direct pharmacological effects on the renal vessels [33–35]
and no peripheral sympathetic inhibition. Intravenous in- ment that does not interfere with GFR autoregulation, as
demonstrated with angiotensin II receptor antagonists.jection of clonidine in normotensive and hypertensive
subjects induces a slight but insignificant reduction in pe- Angiotensin II is a potent constrictor of vascular smooth
muscle cells. In the kidney, the primary action of angio-ripheral and renal vein renin concentration [33, 35]. The
decrease in blood pressure is due to a diminished cardiac tensin II is on the small-diameter resistance arterioles
adjacent to glomeruli. It is well established that both en-output and not to any effects on the total peripheral re-
sistance [34, 35]. Intravenous injection of clonidine (150 dogenous and exogenous angiotensin II affects the pre-
glomerular as well as postglomerular arteriolar tone [48].to 300g) to normotensive and hypertensive nondiabetic
subjects induces no significant change in renal plasma flow Several experimental studies have evaluated the hypoth-
esis that the renin-angiotensin system mediates autoreg-and GFR [2, 29, 33, 35]. Since the relative reduction in
GFR did not exceed 13% of the baseline value in healthy ulation of GFR and renal blood flow (RBF); however, the
results are conflicting. Arendshost and Finn evaluatedhuman controls [28], this level was used as the upper
normal limit for normal GFR autoregulation. the autoregulation of RBF during inhibition of angioten-
sin II in anesthetized rats and concluded that RBF wasThe plasma clearance of 51Cr-EDTA was chosen to
determine GFR because the method is accurate, precise, autoregulated with the same efficiency before and during
the inhibition of angiotensin II [6]. The same results wereand does not require frequent timed urine collections as
do the classic renal clearance procedures. This is impor- obtained by Kaloynides and DiBona, who examined the
role of the renin-angiotensin system on autoregulationtant, since subjects receiving intravenous clonidine can-
not stand up and void within four to five hours after the of GFR in isolated dog kidneys [7]. Inscho et al confirmed
these data by evaluating the effect of candesartan treat-injection because of the orthostatic blood pressure re-
duction. Studies evaluating the circadian rhythm of GFR ment on the autoregulatory capability in angiotensin II-
infused hypertensive rats [8]. Their study revealed that in-have shown that GFR increases from approximately noon
to 1:00 p.m. and decreases thereafter [36, 37]. Two GFR hibition of the AT1 receptors with candesartan provides
protection against angiotensin II-mediated increases inmeasurements were taken on the same day, which could
be affected by the circadian rhythm of GFR. However, arterial blood pressure and prevents the associated dete-
rioration of renal autoregulatory responsiveness. Oneour two GFR measurements were measured as the mean
GFR from 8:00 a.m. to 12:00 p.m. and from 12:30 p.m. study has shown that the renal capability to autoregulate
total blood flow and GFR in the two-kidney, one-clipto 4:30 p.m., and they surrounded the GFR orthophase
of the circadian rhythm, which explains the lack of impact renovascular hypertensive rat is reduced during the AT1
receptor blockade [9], and other studies have shownof the circadian rhythm on GFR in our studies.
A maximum dose of candesartan was decided as the that angiotensin II plays an important role in regulating
tubuloglomerular feedback mechanisms [49, 50]. How-antihypertensive treatment because candesartan is a
highly selective and insurmountable angiotensin II sub- ever, it has been shown that the tubuloglomerular feed-
back mechanism persists during AT1 receptor blockadetype 1 (AT1) receptor blocker, by which a complete sup-
pression of the maximal response to angiotensin II can with candesartan [10]. While the differences in the
above-mentioned studies partly might be explained bybe achieved [38].
Experimental studies suggest that autoregulation in differences in the experimental conditions, the majority
of animal studies have shown that an infusion of angio-GFR is due to autoregulation in two of the main GFR
determinants, that is, renal plasma flow and glomerular tensin II has no significant effects on the autoregulation
of GFR (reviewed by Dworkin et al [49]).capillary hydraulic pressure [1, 39]. The afferent arteriole
plays a pivotal role in regulating glomerular capillary Our study extends the results of most of the animal
studies, indicating that the angiotensin II receptor block-pressure, renal plasma flow and consequently GFR [1,
40–44]. As the ability of the afferent arteriole to dilate or ade does not interfere with autoregulation of GFR. From
a kidney point of view, angiotensin II receptor blockersconstrict is a critical component of the kidney’s defense
against changes in renal perfusion pressure, failure of the and angiotensin-converting enzyme (ACE) inhibitors
therefore may be superior to, for example, calcium chan-afferent arteriole to constrict in the setting of elevated
blood pressure can lead to an enhanced transmission of nels blockers [12], which in animal studies impair auto-
regulation of GFR and thereby diminish the protectionthe systemic pressure into the glomerular capillary net-
work, thus inducing glomerular hypertension [45–47]. against transmission of the systemic blood pressure to
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cium channel blockade on pressure transmission and glomerularthe glomerulus [5, 11, 13, 14]. However, to our knowledge
injury in rat remnant kidneys. J Clin Invest 96:793–800, 1995
no data are available on the effects of calcium channel 12. Navar LG, Inscho EW, Majid DSA, et al: Paracrine regulation
blockers or other antihypertensive drugs on the autoreg- of the renal microcirculation. Physiol Rev 76:425–536, 1996
13. Kloke JH, Branten AJ, Huysmans FT, Wetzels JF: Antihy-ulation of GFR in humans, apart from our present study.
pertensive treatment of patients with proteinuric renal diseases:
Several studies in streptozotocin diabetic rats and dogs Risks of benefits of calcium channel blockers? Kidney Int 53:1559–
have suggested that hyperglycemia induces impaired auto- 1573, 1998
14. Kvam FI, Ofstad J, Iversen BM: Effects of antihypertensive drugsregulation of renal blood flow and GFR [43, 51–53], while
on autoregulation of RBF and glomerular capillary pressure in SHR.others have shown preserved [54] or even enhanced auto- Am J Physiol 275:F576–F584, 1998
regulatory ability [55]. This is in contrast to the more con- 15. Hother-Nielsen O, Faber O, Sørensen NS, Beck-Nielsen H:
Classification of newly diagnosed diabetic patients as insulin-requir-sistent impairment seen after a reduction in functional
ing or non-insulin-requiring based on clinical and biochemical vari-renal mass [56, 57]. Recently, we evaluated the impact of ables. Diabetes Care 11:531–537, 1988
acute changes in blood glucose in type 2 diabetic patients 16. 1999 World Health Organization-International Society of Hyper-
tension guidelines for the management of hypertension. J Hyper-without nephropathy and found that autoregulation was
tens 17:151–183, 1999not affected by blood glucose 15 mmol/L [58]. In the 17. Bro¨chner-Mortensen J: The extracellular fluid volume in normal
present study, there was no difference in glycemic control man determined as the distribution volume of (51Cr)EDTA. Scand
J Clin Lab Invest 42:261–264, 1982during the two examinations.
18. Jensen JS: Intra-individual variation of overnight urinary albuminOur study suggests that candesartan reduces blood pres- excretion in clinically healthy middle-aged individuals. Clin Chim
sure without adversely altering the preserved ability to Acta 243:95–99, 1995
19. Feldt-Rasmussen B: Microalbuminuria and clinical nephropathyautoregulate GFR in hypertensive type 2 diabetic patients
in type 1 (insulin-dependent) diabetes mellitus: Pathophysiologi-without nephropathy. cal mechanisms and intervention studies. Dan Med Bull 36:405–
415, 1989
20. Cohen DL, Close CF, Viberti GC: The variability of overnightACKNOWLEDGMENT
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